These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

687 related articles for article (PubMed ID: 24217510)

  • 41. APP/PS1 mice overexpressing SREBP-2 exhibit combined Aβ accumulation and tau pathology underlying Alzheimer's disease.
    Barbero-Camps E; Fernández A; Martínez L; Fernández-Checa JC; Colell A
    Hum Mol Genet; 2013 Sep; 22(17):3460-76. PubMed ID: 23648430
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tau acts as a mediator for Alzheimer's disease-related synaptic deficits.
    Liao D; Miller EC; Teravskis PJ
    Eur J Neurosci; 2014 Apr; 39(7):1202-13. PubMed ID: 24712999
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reduction of amyloid beta by Aβ3-10-KLH vaccine also decreases tau pathology in 3×Tg-AD mice.
    Zhang HY; Zhu K; Meng Y; Ding L; Wang JC; Yin WC; Yan Y; Cao YP
    Brain Res Bull; 2018 Sep; 142():233-240. PubMed ID: 30077729
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genipin Attenuates Tau Phosphorylation and Aβ Levels in Cellular Models of Alzheimer's Disease.
    Li M; Cai N; Gu L; Yao L; Bi D; Fang W; Lin Z; Wu Y; Xu H; Li H; Hu Z; Xu X
    Mol Neurobiol; 2021 Aug; 58(8):4134-4144. PubMed ID: 33948899
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Emerging beta-amyloid therapies for the treatment of Alzheimer's disease.
    Conway KA; Baxter EW; Felsenstein KM; Reitz AB
    Curr Pharm Des; 2003; 9(6):427-47. PubMed ID: 12570807
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease.
    Manczak M; Reddy PH
    Hum Mol Genet; 2012 Dec; 21(23):5131-46. PubMed ID: 22926141
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of tau protein in Alzheimer's disease: The prime pathological player.
    Muralidar S; Ambi SV; Sekaran S; Thirumalai D; Palaniappan B
    Int J Biol Macromol; 2020 Nov; 163():1599-1617. PubMed ID: 32784025
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Human tau increases amyloid β plaque size but not amyloid β-mediated synapse loss in a novel mouse model of Alzheimer's disease.
    Jackson RJ; Rudinskiy N; Herrmann AG; Croft S; Kim JM; Petrova V; Ramos-Rodriguez JJ; Pitstick R; Wegmann S; Garcia-Alloza M; Carlson GA; Hyman BT; Spires-Jones TL
    Eur J Neurosci; 2016 Dec; 44(12):3056-3066. PubMed ID: 27748574
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Status and future directions of clinical trials in Alzheimer's disease.
    Plascencia-Villa G; Perry G
    Int Rev Neurobiol; 2020; 154():3-50. PubMed ID: 32739008
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The past, present, and future of disease-modifying therapies for Alzheimer's disease.
    Suzuki K; Iwata A; Iwatsubo T
    Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(10):757-771. PubMed ID: 29225305
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The interactions of p53 with tau and Aß as potential therapeutic targets for Alzheimer's disease.
    Jazvinšćak Jembrek M; Slade N; Hof PR; Šimić G
    Prog Neurobiol; 2018 Sep; 168():104-127. PubMed ID: 29733887
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice.
    Rasool S; Martinez-Coria H; Wu JW; LaFerla F; Glabe CG
    J Neurochem; 2013 Aug; 126(4):473-82. PubMed ID: 23672786
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tau immunotherapies for Alzheimer's disease.
    Hoskin JL; Sabbagh MN; Al-Hasan Y; Decourt B
    Expert Opin Investig Drugs; 2019 Jun; 28(6):545-554. PubMed ID: 31094578
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reducing Aβ load and tau phosphorylation: Emerging perspective for treating Alzheimer's disease.
    Kalra J; Khan A
    Eur J Pharmacol; 2015 Oct; 764():571-581. PubMed ID: 26209363
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Calcium signaling in Alzheimer's disease & therapies.
    Tong BC; Wu AJ; Li M; Cheung KH
    Biochim Biophys Acta Mol Cell Res; 2018 Nov; 1865(11 Pt B):1745-1760. PubMed ID: 30059692
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease.
    Barage SH; Sonawane KD
    Neuropeptides; 2015 Aug; 52():1-18. PubMed ID: 26149638
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reduction of advanced tau-mediated memory deficits by the MAP kinase p38γ.
    Ittner A; Asih PR; Tan ARP; Prikas E; Bertz J; Stefanoska K; Lin Y; Volkerling AM; Ke YD; Delerue F; Ittner LM
    Acta Neuropathol; 2020 Sep; 140(3):279-294. PubMed ID: 32725265
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
    Merino JJ; Muñetón-Gómez V; Alvárez MI; Toledano-Díaz A
    Curr Alzheimer Res; 2016; 13(4):403-12. PubMed ID: 26567742
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tau-targeted treatment strategies in Alzheimer's disease.
    Götz J; Ittner A; Ittner LM
    Br J Pharmacol; 2012 Mar; 165(5):1246-59. PubMed ID: 22044248
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models.
    Götz J; Schild A; Hoerndli F; Pennanen L
    Int J Dev Neurosci; 2004 Nov; 22(7):453-65. PubMed ID: 15465275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.